Intuitive Surgical, Inc. ISRG
405.18
5.66
1.42%
as of 25 Sep
- Market cap
- $140.7B
- P/E
- 45.8×
Follow ISRG
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
58.16 | 70.71 | 55.08 | 44.99 |
P/S ratio |
16.59 | 20.08 | 15.46 | 12.76 | |
P/FCF ratio |
70.22 | 81.16 | 56.80 | 43.08 | |
P/Operating CF |
189.63 | 226.48 | 179.41 | 132.72 | |
P/B ratio |
9.36 | 11.27 | 9.30 | 7.70 | |
Price to Tangible BV |
10.05 | 12.09 | 10.30 | 8.49 | |
EV/Sales |
16.08 | 19.49 | 15.03 | 12.29 | |
EV/EBITDA |
45.00 | 54.16 | 40.20 | 31.88 | |
EV/Operating CF |
52.21 | 64.74 | 47.34 | 36.59 | |
EV/FCF |
68.06 | 78.77 | 55.23 | 41.49 | |
Quick Ratio |
3.42 | 3.72 | 3.20 | 3.58 | |
Current Ratio |
4.73 | 4.87 | 4.61 | 4.96 | |
Net Debt/EBITDA |
(5.13) | (5.61) | (4.32) | (4.37) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.52 | 0.51 | 0.54 | 0.54 | |
Operating CF/Net income |
1.19 | 1.12 | 1.11 | 1.30 | |
Capex/Depreciation |
(0.53) | (0.84) | (0.30) | (0.51) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
13.15% | 12.31% | 13.06% | 12.81% | |
Selling, General and Administrative Expense of Revenue |
22.89% | 23.97% | 22.13% | 21.36% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.08 | 0.08 | |
Share Based Compensation of Revenue |
8.12% | 7.09% | 7.56% | 7.26% | |
Graham Net Nets |
0.04 | 0.04 | 0.04 | 0.05 | |
Graham Number |
90.93 | 95.18 | 96.63 | 101.38 | |
Earnings Yield |
1.72% | 1.41% | 1.82% | 2.22% | |
Free Cash Flow Yield |
1.42% | 1.23% | 1.76% | 2.32% | |
Revenue per Share |
7.03 | 8.03 | 7.81 | 8.17 | |
Operating CF per Share |
2.36 | 2.50 | 2.57 | 3.00 | |
Capex per Share |
(0.30) | (0.46) | (0.16) | (0.32) | |
Free Cash Flow per Share |
2.06 | 2.05 | 2.41 | 2.68 | |
Cash per Share |
13.77 | 16.63 | 12.73 | 14.73 | |
Shareholders Equity per Share |
47.79 | 50.27 | 49.58 | 51.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
47.79 | 50.27 | 49.58 | 51.67 | |
Free Cash Flow |
735.60 | 730.00 | 854.60 | 948.40 | |
Working Capital |
6,722.10 | 7,773.30 | 6,898.50 | 7,619.80 | |
Capital Expenditures |
(105.40) | (162.50) | (57.30) | (112.60) | |
Net Current Asset Value |
6,215.60 | 7,262.50 | 6,295.70 | 6,963.80 | |
EV/EBIT |
54.89 | 66.61 | 49.36 | 39.29 | |
Capex to Sales |
0.04 | 0.06 | 0.02 | 0.04 | |
Net Profit Margin |
28.12% | 27.73% | 29.65% | 28.29% | |
Price to Operating Income |
56.63 | 68.62 | 50.77 | 40.80 | |
| Other line items | |||||
Average Receivables |
1,206.35 | 1,376.35 | 1,408.55 | 1,471.20 | |
Average Payables |
254.95 | 224.25 | 304.55 | 272.00 | |
Average Inventory |
1,631.80 | 1,663.60 | 1,749.35 | 1,847.85 | |
Average Assets |
18,547.60 | 19,600.95 | 19,665.70 | 20,519.90 | |
Average Common Equity |
16,359.80 | 17,235.65 | 17,402.45 | 18,125.40 |
Columns are period end dates